support@mellalta.com   +1 (304) 306-0723

JNJ‑4528-Investigation Treatment for R/R Multiple Myeloma, has it all (Breakthrough Designation, Effective Results & Excited KOLs)

JNJ‑4528

Legend Biotech Corporation, announced the updated results from the Janssen sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528) in multiple myeloma. There is something interesting about the drug, JNJ-4528 […]

Read More

Marker Therapeutics speaks on MultiTAA, therapy for Pancreatic Adenocarcinoma, the silent killer

The 56th session of the American Society of Clinical Oncology (ASCO) was forced virtually this year due to the COVID19. The ASCO20 Virtual Scientific Program meeting was rounded up with almost 250 virtual oral abstract […]

Read More

Get In Touch

Let's keep the conversation going